Malignant mesothelioma is a unusual and fast moving growth where no successful treatment has been discovered even with the discovery of many possible molecular and genetic targets. The final stages of Malignant pleural mesothelioma diagnosis and the long latency that between exposures and diagnosis have made it difficult to comprehensively evaluate the role of risk factors and the insuing molecular effects.

A lot of medical centers are beginning to see increasing numbers of people with malignant mesothelioma. This presents pathologists involved in making the diagnosis with a number of problems, that are separated into those encountered in making the distinction between cancer of the mesothelium and benign changes and those experienced in setting apart cancer of the mesothelium from other types of epithelial and tissue tumors that connect. Immunohistochemistry is a major factor in making the diagnosis, however, it should be understood with regards to the medical setting and radiological characteristics, and with an understanding of the extensive morphological variations existing in mesothelioma.

Malignant mesothelioma is a primary cancer of the serosal cavities, an anatomic area that is often affected by metastatic disease, mostly from primary carcinomas of the ovary, lung and breast. Developments in immunohistochemistry have resulted in improvement in diagnostic sensitivity and cancer of the mesothelium in regards to histological and cytological material. As of late, the authors group applied increased levels of throughput technology to the classification of new markers that might assist in differentiating mesothelioma from ovarian and peritoneal serous carcinoma, tumors with closely related histogenesis and antigenic profile. Together with the improved medical devices obtainable for serosal carcinoma diagnosis, realizing the biology of malignant mesothelioma has been accruing as of late.